Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and Azathioprine for GLILD in CVID
NCT02789397Phase 2Withdrawn
- Sponsor
- Medical College of Wisconsin
- Start
- May 2016
- Primary completion
- Mar 2018
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
A Phase 2 trial of rituximab, azathioprine in Granulomatous and Lymphocytic Interstitial Lung Disease (GLILD), sponsored by Medical College of Wisconsin. Planned start May 2016; status: withdrawn.
02
Drugs
rituximabazathioprine
03
Conditions
Granulomatous and Lymphocytic Interstitial Lung Disease (GLILD)
Beyond the preview
Go deeper on NCT02789397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02789397.